← All trials
NCT05896748
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2022
- Primary completion
- Apr 18, 2023
- Completion date
- Sep 14, 2023
- First posted
- Jun 9, 2023
- Last posted
- Dec 22, 2023
- Enrollment
- 93
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ViiV HealthcareLead sponsor
- ViiV HealthcareStudy director
- GlaxoSmithKlineCollaborator
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.